References

  1. 1.Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 suppl 2):S102-S138.
  2. 2.Zhou XD, Chen QF, Yang W, et al. Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021. EClinicalMedicine. 2024;76:102848.
  3. 3.Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-562.
  4. 4.Razak F, Anand SS, Shannon H, et al. Defining obesity cut points in a multiethnic population. Circulation. 2007;115(16):2111-2118.
  5. 5.WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163.
  6. 6.Hannon TS, Arslanian SA. Obesity in adolescents. N Engl J Med. 2023;389(3):251-261.
  7. 7.Wang JS, Xia PF, Ma MN, et al. Trends in the prevalence of metabolically healthy obesity among US adults, 1999-2018. JAMA Netw Open. 2023;6(3):e232145.
  8. 8.Emmerich SD, Fryar CD, Stierman B, et al. Obesity and severe obesity prevalence in adults: United States, August 2021-August 2023. NCHS Data Brief. 2024(508):10.15620/cdc/159281.
  9. 9.Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13-27.
  10. 10.Li M, Gong W, Wang S, et al. Trends in body mass index, overweight and obesity among adults in the USA, the NHANES from 2003 to 2018: a repeat cross-sectional survey. BMJ Open. 2022;12(12):e065425.
  11. 11.Liu B, Du Y, Wu Y, et al. Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study. BMJ. 2021;372(365):n365.
  12. 12.Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 prepandemic data files—development of files and prevalence estimates for selected health outcomes. Natl Health Stat Rep. 2021;158:10.15620/cdc:106273.
  13. 13.Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138(1):24-32.
  14. 14.Stephenson J, Smith CM, Kearns B, et al. The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study. BMC Public Health. 2021;21(1):1990.
  15. 15.Ward ZJ, Bleich SN, Long MW, et al. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307.
  16. 16.Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021;27(3):354-366.
  17. 17.Okunogbe A, Nugent R, Spencer G, et al. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022;7(9):e009773.
  18. 18.Kitahara CM, Flint AJ, Berrington de González A, et al. Association between class III obesity (BMI 40–59.9 kg/m2) and mortality: a pooled analysis of 20 prospective studies. PLoS Med. 2014;11(7):e1001673.
  19. 19.Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.
  20. 20.Javed Z, Valero-Elizondo J, Maqsood MH, et al. Social determinants of health and obesity: findings from a national study of US adults. Obesity (Silver Spring). 2022;30(2):491-502.
  21. 21.Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363-370.
  22. 22.Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: a review. JAMA. 2023;330(20):2000-2015.
  23. 23.American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity. BMJ Open Diabetes Res Care. 2026;13(suppl 1):e005729.
  24. 24.McBurney MI, Cho CE. Understanding the role of the human gut microbiome in overweight and obesity. Ann N Y Acad Sci. 2024;1540(1):61-88.
  25. 25.Sasidharan Pillai S, Gagnon CA, Foster C, et al. Exploring the gut microbiota: key insights into its role in obesity, metabolic syndrome, and type 2 diabetes. J Clin Endocrinol Metab. 2024;109(11):2709-2719.
  26. 26.Perrone P, D’Angelo S. Gut microbiota modulation through Mediterranean diet foods: implications for human health. Nutrients. 2025;17(6):948.
  27. 27.Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203.
  28. 28.Curry SJ, Krist AH, Owens DK, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(11):1163-1171.
  29. 29.Nicholson WK, Silverstein M, Wong JB, et al. Interventions for high body mass index in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2024;332(3):226-232.
  30. 30.Wu Y, Li D, Vermund SH. Advantages and limitations of the body mass index (BMI) to assess adult obesity. Int J Environ Res Public Health. 2024;21(6):757.
  31. 31.Gnatiuc L, Alegre-Díaz J, Wade R, et al. General and abdominal adiposity and mortality in Mexico City: a prospective study of 150,000 adults. Ann Intern Med. 2019;171(6):397-405.
  32. 32.Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: what is the path forward? Curr Obes Rep. 2024;13(3):584-595.
  33. 33.Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
  34. 34.Suliga E, Ciesla E, Głuszek-Osuch M, et al. The usefulness of anthropometric indices to identify the risk of metabolic syndrome. Nutrients. 2019;11(11):2598.
  35. 35.Xu J, Zhang L, Wu Q, et al. Body roundness index is a superior indicator to associate with the cardio-metabolic risk: evidence from a cross-sectional study with 17,000 Eastern-China adults. BMC Cardiovasc Disord. 2021;21(1):97.
  36. 36.Bergman RN, Stefanovski D, Buchanan TA, et al. A better index of body adiposity. Obesity (Silver Spring). 2011;19(5):1083-1089.
  37. 37.Nadolsky K, Addison B, Agarwal M, et al. American Association of Clinical Endocrinology consensus statement: addressing stigma and bias in the diagnosis and management of patients with obesity/adiposity-based chronic disease and assessing bias and stigmatization as determinants of disease severity. Endocr Pract. 2023;29(6):417-427.
  38. 38.Kane RM, Williams SB, Reynolds K, et al. Patient perceived weight stigma and patient-centered language use preferences: a cross-sectional mixed methods analysis conducted in a large academic medical center. PLoS One. 2025;20(2):e0314269.
  39. 39.Puhl RM. What words should we use to talk about weight? A systematic review of quantitative and qualitative studies examining preferences for weight-related terminology. Obes Rev. 2020;21(6):e13008.
  40. 40.Acosta A, Streett S, Kroh MD, et al. White paper AGA: POWER—Practice Guide on Obesity and Weight Management, Education, and Resources. Clin Gastroenterol Hepatol. 2017;15(5):631-649.e10.
  41. 41.Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393(7):683-698.
  1. 1.Loureiro ML, Nayga RMJ. Obesity, weight loss, and physician’s advice. Soc Sci Med. 2006;62(10):2458-2468.
  2. 2.Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: a review. JAMA. 2023;330(20):2000-2015.
  3. 3.Jay M, Gillespie C, Schlair S, et al. Physicians’ use of the 5As in counseling obese patients: is the quality of counseling associated with patients’ motivation and intention to lose weight? BMC Health Serv Res. 2010;10:159.
  4. 4.Gudzune KA, Bennett WL, Cooper LA, et al. Perceived judgment about weight can negatively influence weight loss: a cross-sectional study of overweight and obese patients. Prev Med. 2014;62:103-107.
  5. 5.Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 suppl 2):S102-S138.
  6. 6.Mifflin MD, St Jeor ST, Hill LA, et al. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr. 1990;51(2):241-247.
  7. 7.Medscape tools and reference calculators. Mifflin-St Jeor equation calculator. Medscape. Accessed June 16, 2025. https://reference.medscape.com/calculator/846/mifflin-st-jeor-equation#
  8. 8.Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187-194.
  9. 9.Spring B, Champion KE, Acabchuk R, et al. Self-regulatory behaviour change techniques in interventions to promote healthy eating, physical activity, or weight loss: a meta-review. Health Psychol Rev. 2021;15(4):508-539.
  10. 10.Teixeira PJ, Carraça EV, Marques MM, et al. Successful behavior change in obesity interventions in adults: a systematic review of self-regulation mediators. BMC Med. 2015;13:84.
  11. 11.Paixão C, Dias CM, Jorge R, et al. Successful weight loss maintenance: a systematic review of weight control registries. Obes Rev. 2020;21(5):e13003.
  12. 12.Deslippe AL, Soanes A, Bouchaud CC, et al. Barriers and facilitators to diet, physical activity and lifestyle behavior intervention adherence: a qualitative systematic review of the literature. Int J Behav Nutr Phys Act. 2023;20(1):14.
  13. 13.Wurtman J, Wurtman R. The trajectory from mood to obesity. Curr Obes Rep. 2018;7(1):1-5.
  14. 14.Ge L, Sadeghirad B, Ball GDC, et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ. 2020;369:m696.
  15. 15.Laudenslager M, Chaudhry ZW, Rajagopal S, et al. Commercial weight loss programs in the management of obesity: an update. Curr Obes Rep. 2021;10(2):90-99.
  16. 16.Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014;312(9):923-933.
  17. 17.Tran E, Dale HF, Jensen C, et al. Effects of plant-based diets on weight status: a systematic review. Diabetes Metab Syndr Obes. 2020;13:3433-3448.
  18. 18.Toro-Ramos T, Lee DH, Kim Y, et al. Effectiveness of a smartphone application for the management of metabolic syndrome components focusing on weight loss: a preliminary study. Metab Syndr Relat Disord. 2017;15(9):465-473.
  19. 19.Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686.
  20. 20.Centers for Disease Control and Prevention. Diabetes Prevention Recognition Program Registry. Registry of all recognized organizations. May 15, 2024. Accessed October 30, 2025. https://dprp.cdc.gov/registry
  21. 21.Di Rosa C, Lattanzi G, Spiezia C, et al. Mediterranean diet versus very low-calorie ketogenic diet: effects of reaching 5% body weight loss on body composition in subjects with overweight and with obesity—a cohort study. Int J Environ Res Public Health. 2022;19(20):13040.
  22. 22.Doundoulakis I, Farmakis IT, Theodoridis X, et al. Effects of dietary interventions on cardiovascular outcomes: a network meta-analysis. Nutr Rev. 2024;82(6):715-725.
  23. 23.Liu D, Huang Y, Huang C, et al. Calorie restriction with or without time-restricted eating in weight loss. N Engl J Med. 2022;386(16):1495-1504.
  24. 24.Črešnovar T, Habe B, Jenko Pražnikar Z, et al. Effectiveness of time-restricted eating with caloric restriction vs. caloric restriction for weight loss and health: meta-analysis. Nutrients. 2023;15(23):4911.
  25. 25.Steger FL, Jamshed H, Bryan DR, et al. Early time-restricted eating affects weight, metabolic health, mood, and sleep in adherent completers: a secondary analysis. Obesity (Silver Spring). 2023;31(suppl 1):96-107.
  26. 26.Gudzune KA, Clark JM. Role of commercial weight-loss programs in medical management of obesity. Endocrinol Metab Clin North Am. 2020;49(2):275-287.
  27. 27.Chin SO, Keum C, Woo J, et al. Successful weight reduction and maintenance by using a smartphone application in those with overweight and obesity. Sci Rep. 2016;6:34563.
  28. 28.Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8):873-934.
  29. 29.Bellicha A, van Baak MA, Battista F, et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: an overview of 12 systematic reviews and 149 studies. Obes Rev. 2021;22(suppl 4):e13256.
  30. 30.Andreato LV, Esteves JV, Coimbra DR, et al. The influence of high-intensity interval training on anthropometric variables of adults with overweight or obesity: a systematic review and network meta-analysis. Obes Rev. 2019;20(1):142-155.
  31. 31.Patel ML, Wakayama LN, Bennett GG. Self-monitoring via digital health in weight loss interventions: a systematic review among adults with overweight or obesity. Obesity (Silver Spring). 2021;29(3):478-499.
  32. 32.Tate DF, Crane MM, Espeland MA, et al. Sustaining ehealth engagement in a multi-year weight gain prevention intervention. Obes Sci Pract. 2019;5(2):103-110.
  33. 33.Nishi SK, Kavanagh ME, Ramboanga K, et al. Effect of digital health applications with or without gamification on physical activity and cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials. EClinicalMedicine. 2024;76:102798.
  34. 34.Pangarkar T. Smart wearables statistics 2025 by devices, technology, usage. Market.us Scoop. Updated January 14, 2025. Accessed October 30, 2025. https://scoop.market.us/smart-wearables-statistics/
  35. 35.Jakicic JM, Davis KK, Rogers RJ, et al. Effect of wearable technology combined with a lifestyle intervention on long-term weight loss: the IDEA randomized clinical trial. JAMA. 2016;316(11):1161-1171.
  36. 36.Ferguson T, Olds T, Curtis R, et al. Effectiveness of wearable activity trackers to increase physical activity and improve health: a systematic review of systematic reviews and meta-analyses. Lancet Digit Health. 2022;4(8):e615-e626.
  37. 37.Pujia C, Ferro Y, Mazza E, et al. The role of mobile apps in obesity management: systematic review and meta-analysis. J Med Internet Res. 2025;27:e66887.
  38. 38.Spring B, Pfammatter AF, Scanlan L, et al. An adaptive behavioral intervention for weight loss management: a randomized clinical trial. JAMA. 2024;332(1):21-30.
  39. 39.Wu Y, Zhai L, Zhang D. Sleep duration and obesity among adults: a meta-analysis of prospective studies. Sleep Med. 2014;15(12):1456-1462.
  40. 40.Larsen SC, Horgan G, Mikkelsen MK, et al. Consistent sleep onset and maintenance of body weight after weight loss: an analysis of data from the NoHoW trial. PLoS Med. 2020;17(7):e1003168.
  41. 41.Rouyard T, Yoda E, Akksilp K, et al. Effects of workplace interventions on sedentary behaviour and physical activity: an umbrella review with meta-analyses and narrative synthesis. Lancet Public Health. 2025;10(4):e295-e308.
  1. 1.American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of Care in overweight and obesity. BMJ Open Diabetes Res Care. 2026;13(suppl 1):e005729.
  2. 2.Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225.
  3. 3.Moiz A, Levett JY, Filion KB, et al. Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Am J Cardiol. 2024;222:121-130.
  4. 4.Gudzune KA, Kushner RF. Medications for obesity: a review. JAMA. 2024;332(7):571-584.
  5. 5.Alhomoud IS, Talasaz AH, Chandrasekaran P, et al. Incretin hormone agonists: current and emerging pharmacotherapy for obesity management. Pharmacotherapy. 2024;44(9):738-752.
  6. 6.Kelly AS, Armstrong SC, Michalsky MP, et al. Obesity in adolescents: a review. JAMA. 2024;332(9):738-748.
  7. 7.Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: a review. JAMA. 2023;330(20):2000-2015.
  8. 8.UpToDate Lexidrug. Phentermine. Accessed February 27, 2025. https://online.lexi.com
  9. 9.Hollander P, Bays HE, Rosenstock J, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40(5):632-639.
  10. 10.Saxon DR, Iwamoto SJ, Mettenbrink CJ, et al. Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015. Obesity (Silver Spring). 2019;27(12):1975-1981.
  11. 11.Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019;27(4):591-602.
  12. 12.Bray GA, Purnell JQ. An historical review of steps and missteps in the discovery of anti-obesity drugs. In: Feingold KR, Ahmed SF, Anawalt B, et al, eds. Endotext. MDText.com, Inc; 2000.
  13. 13.UpToDate Lexidrug. Qsymia. Accessed February 27, 2025 https://online.lexi.com
  14. 14.Benedictus B, Pratama VK, Purnomo CW, et al. Efficacy of oral medication in weight loss management: a systematic review and network meta-analysis. Clin Ther. 2025;47(4):316-329.
  15. 15.UpToDate Lexidrug. Contrave. Accessed May 30, 2025. https://online.lexi.com
  16. 16.UpToDate Lexidrug. Orlistat. Accessed May 30, 2025. https://online.lexi.com
  17. 17.Ansari HUH, Qazi SU, Sajid F, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pract. 2024;30(2):160-171.
  18. 18.Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-437.
  19. 19.Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503.
  20. 20.Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;403(10434):e21-e31.
  21. 21.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.
  22. 22.Hernandez I, Wright DR, Guo J, et al. Centers for Medicare and Medicaid. Part D coverage of anti-obesity medications with medically accepted indications. J Gen Intern Med. 2024;39(2):306-308.
  23. 23.Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739.
  24. 24.Feldman-Billard S. What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes. Diabetes Metab. 2025;51(4):101664.
  25. 25.Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
  26. 26.Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087.
  27. 27.UpToDate Lexidrug. Wegovy. Accessed February 27, 2025. https://online.lexi.com
  28. 28.Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205.
  29. 29.de Mesquita YLL, Pera Calvi I, Reis Marques I, et al. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes (Lond). 2023;47(10):883-892.
  30. 30.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
  31. 31.Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48.
  32. 32.Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36.
  33. 33.Liu L, Li Z, Ye W, et al. Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine. 2024;79:103020.
  34. 34.Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025;77(1):100002.
  35. 35.Melson E, Ashraf U, Papamargaritis D, et al. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025;49(3):433-451.
  36. 36.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806.
  37. 37.Batsis JA, Apolzan JW, Bagley PJ, et al. A systematic review of dietary supplements and alternative therapies for weight loss. Obesity (Silver Spring). 2021;29(7):1102-1113.
  38. 38.Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.
  39. 39.Lee JM, Sharifi M, Oshman L, et al. Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023. JAMA. 2024;331(23):2041-2043.
  40. 40.Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6):10.1056/evidoa2200014.
  41. 41.Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128.
  42. 42.Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257.
  43. 43.Carroll DG. The risks and benefits of managing obesity in older adults. Am J Health Syst Pharm. 2025;82(9):e419-e425.
  44. 44.Wu H, Yang W, Guo T, et al. Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Med. 2025;23(1):398.
  45. 45.Fujioka K, Harris SR. Barriers and solutions for prescribing obesity pharmacotherapy. Endocrinol Metab Clin North Am. 2020;49(2):303-314.
  46. 46.US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilise. Updated April 28, 2025. Accessed February 9, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  1. 1.Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356.
  2. 2.Clapp B, Ponce J, Corbett J, et al. American Society for Metabolic and Bariatric Surgery 2022 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2024;20(5):425-431.
  3. 3.Muniraj T, Day LW, Teigen LM, et al. AGA clinical practice guidelines on intragastric balloons in the management of obesity. Gastroenterology. 2021;160(5):1799-1808.
  4. 4.Banerjee ES, Schroeder R, Harrison TD. Metabolic surgery for adult obesity: common questions and answers. Am Fam Physician. 2022;105(6):593-601.
  5. 5.Sudan R, Maciejewski ML, Wilk AR, et al. Comparative effectiveness of primary bariatric operations in the United States. Surg Obes Relat Dis. 2017;13(5):826-834.
  6. 6.Khorgami Z, Aminian A, Shoar S, et al. Cost of bariatric surgery and factors associated with increased cost: an analysis of national inpatient sample. Surg Obes Relat Dis. 2017;13(8):1284-1289.
  7. 7.Ng AP, Bakhtiyar SS, Verma A, et al. Cost variation in bariatric surgery across the United States. Am Surg. 2023;89(10):4061-4065.
  8. 8.Borisenko O, Adam D, Funch-Jensen P, et al. Bariatric surgery can lead to net cost savings to health care systems: results from a comprehensive European decision analytic model. Obes Surg. 2015;25(9):1559-1568.
  9. 9.Pratt JSA, Browne A, Browne NT, et al. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis. 2018;14(7):882-901.
  10. 10.Carter J, Chang J, Birriel TJ, et al. ASMBS position statement on preoperative patient optimization before metabolic and bariatric surgery. Surg Obes Relat Dis. 2021;17(12):1956-1976.
  11. 11.American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes–2025. Diabetes Care. 2025;48(1 suppl 1):S167-S180.
  12. 12.Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.
  13. 13.Alqahtani A, Elahmedi M, Al-Qahtani AR. Laparoscopic sleeve gastrectomy in children younger than 14 years: refuting the concerns. Ann Surg. 2016;263(2):312-319.
  14. 14.Inge TH, Courcoulas AP, Jenkins TM, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113-123.
  15. 15.Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174772 participants. Lancet. 2021;397(10287):1830-1841.
  16. 16.Aminian A, Chang J, Brethauer SA, et al. ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30-35 kg/m2). Surg Obes Relat Dis. 2018;14(8):1071-1087.
  17. 17.Junquera Bañares S, Ramírez Real L, Camuñas Segovia J, et al. Evaluation of quality of life, weight loss and evolution of comorbidities at 6 years after bariatric surgery. Endocrinol Diabetes Nutr (Engl Ed). 2021;68(7):501-508.
  18. 18.Al Oweidat K, Toubasi AA, Tawileh RBA, et al. Bariatric surgery and obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath. 2023;27(6):2283-2294.
  19. 19.Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031-2042.
  20. 20.Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA. 2022;327(24):2423-2433.
  21. 21.Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641-651.
  22. 22.Arterburn DE, Telem DA, Kushner RF, et al. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879-887.
  23. 23.Campos GM, Khoraki J, Browning MG, et al. Changes in utilization of bariatric surgery in the united states from 1993 to 2016. Ann Surg. 2020;271(2):201-209.
  24. 24.Castaneda D, Popov VB, Wander P, et al. Risk of suicide and self-harm is increased after bariatric surgery—a systematic review and meta-analysis. Obes Surg. 2019;29(1):322-333.
  25. 25.Gondal AB, Hsu CH, Khoubyari R, et al. Development of a bariatric surgery specific risk assessment tool for perioperative myocardial infarction. Surg Obes Relat Dis. 2019;15(3):462-468.
  26. 26.Bilimoria KY, Liu Y, Paruch JL, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg. 2013;217(5):833-42.e1-3.
  27. 27.Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures—2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247.
  28. 28.Horvath CM, Jossen J, Kröll D, et al. Prevalence and prediction of obstructive sleep apnea prior to bariatric surgery—gender-specific performance of four sleep questionnaires. Obes Surg. 2018;28(9):2720-2726.
  29. 29.Riedinger CJ, Zite NB, Overby DW, et al. Optimizing contraceptive access for women undergoing bariatric surgery. Surg Obes Relat Dis. 2020;16(12):2082-2087.
  30. 30.Duane M, Stanford JB, Porucznik CA, et al. Fertility awareness-based methods for women’s health and family planning. Front Med (Lausanne). 2022;9:858977.
  31. 31.Felix AS, Gaudet MM, La Vecchia C, et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer. 2015;136(5):e410-e422.
  32. 32.Snoek KM, Steegers-Theunissen RPM, Hazebroek EJ, et al. The effects of bariatric surgery on periconception maternal health: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(6):1030-1055.
  33. 33.Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertil Steril. 2015;104(5):1116-1126.
  34. 34.Carreira A, Araújo B, Lavrador M, et al. From bariatric surgery to conception: the ideal timing to optimize fetal weight. Obes Surg. 2023;33(9):2859-2865.
  35. 35.Angus R, Leow TW, Humes D, et al. The relationship between alcohol consumption and outcomes after gastrointestinal surgery: a systematic review and meta-analysis. Alcohol Alcohol. 2025;60(2):agaf002.
  36. 36.Tack J, Deloose E. Complications of bariatric surgery: dumping syndrome, reflux and vitamin deficiencies. Best Pract Res Clin Gastroenterol. 2014;28(4):741-749.
  37. 37.Arts J, Caenepeel P, Bisschops R, et al. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping. Clin Gastroenterol Hepatol. 2009;7(4):432-437.
  38. 38.Lau C, van Kesteren C, Smeenk R, et al. Impact of bariatric surgery in the short and long term: a need for time-dependent dosing of drugs. Obes Surg. 2023;33(10):3266-3302.
  39. 39.Kim EY. Definition, mechanisms and predictors of weight loss failure after bariatric surgery. J Metab Bariatr Surg. 2022;11(2):39-48.
  40. 40.Kramer CK, Retnakaran M, Viana LV. Effect of glucagon-like peptide-1 receptor agonists (GLP-1RA) on weight loss following bariatric treatment. J Clin Endocrinol Metab. 2024;109(8):e1634-e1641.
  41. 41.Nie Y, Zhang Y, Liu B, et al. Glucagon-like peptide-1 receptor agonists for the treatment of suboptimal initial clinical response and weight gain recurrence after bariatric surgery: a systematic review and meta-analysis. Obes Surg. 2025;35(3):808-822.

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.